SEMA3F and breast cancer: This finding is in agreement with previous reports in hepatocarcinoma [30, 31] and in other types of cancer, including BC [32], and reveals SEMA3F and its coreceptors as candidates for poor prognostic markers in cancer and possible cancer therapeutic targets.